Publications by authors named "E C Breij"
An Antibody-Drug Conjugate Directed to Tissue Factor Shows Preclinical Antitumor Activity in Head and Neck Cancer as a Single Agent and in Combination with Chemoradiotherapy.
Mol Cancer Ther
February 2024
Unlabelled: Head and neck squamous cell carcinoma (HNSCC) is a solid tumor type that arises in the squamous epithelial cells lining the mucosal surfaces of the upper aerodigestive tract. Long-term survival of patients with advanced disease stage remains disappointing with current treatment options. We show that tissue factor is abundantly expressed on patient-derived HNSCC cell lines, xenograft tumor material, and tumor biopsies from patients with HNSCC.
View Article and Find Full Text PDFBackground: HexaBody®-CD38 (GEN3014) is a hexamerization-enhanced human IgG1 that binds CD38 with high affinity. The E430G mutation in its Fc domain facilitates the natural process of antibody hexamer formation upon binding to the cell surface, resulting in increased binding of C1q and potentiated complement-dependent cytotoxicity (CDC).
Methods: Co-crystallization studies were performed to identify the binding interface of HexaBody-CD38 and CD38.
Article Synopsis
- Chronic lymphocytic leukemia (CLL) is a challenging disease that leads to a weakened immune system and makes patients more prone to infections and less responsive to immunotherapies; however, new treatments with BTK inhibitors and venetoclax have shown promise in improving outcomes.
- Epcoritamab, a bispecific antibody that targets both CD3 and CD20, has shown strong clinical effects in treating relapsed non-Hodgkin lymphoma and is being studied for its potential to enhance CLL therapy, particularly when combined with existing treatments.
- Research indicates that epcoritamab promotes T-cell activity and can effectively reduce CLL cellular presence in mouse models, making it a promising candidate for combination therapy with BTK inhibitors
Article Synopsis
- Elevated tissue factor (TF) expression is linked to poor prognosis in various solid cancers, with a systematic analysis conducted to compare its prevalence and localization across multiple tumor types for the first time.
- The study involved patient biopsies from different cancers, revealing that TF was most prominent in pancreatic, cervical, colon, glioblastoma, head and neck squamous cell carcinoma, and non-small cell lung cancer, with varying expression patterns noted in individual cases.
- Findings indicate that while TF is widely present across solid tumors and remains consistent over time for most patients, individual variability exists, suggesting potential implications for disease progression and treatment.
Therapeutic antibodies have broad indications across diverse disease states, such as oncology, autoimmune diseases, and infectious diseases. New research continues to identify antibodies with therapeutic potential as well as methods to improve upon endogenous antibodies and to design antibodies de novo. On April 27-30, 2022, experts in antibody research across academia and industry met for the Keystone symposium "Antibodies as Drugs" to present the state-of-the-art in antibody therapeutics, repertoires and deep learning, bispecific antibodies, and engineering.
View Article and Find Full Text PDF